Newsroom

June 2016

• In The News Jun 09, 2016

  Novartis Access perspectives: Expanding access to healthcare: What will it really take?

  A Medium post by Steve Davis, CEO of PATH
• 
  Story Jun 09, 2016 Discovery

  Cancer researchers ready to aim for cures

  New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.

• 
  Story Jun 09, 2016 Discovery

  Confidence led this researcher to swim against the current

  A researcher reflects on her successful journey from Venezuela to the US in which she became a doctor, a scientist, and a mother.

• Press release Jun 09, 2016

  New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products

  Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
• Press release Jun 08, 2016

  Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention

  Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment  Migraine is a leading cause of disability,…
• 
  Story Jun 08, 2016 Patient Perspectives

  The future of chronic myeloid leukemia is evolving

• Press release Jun 08, 2016

  Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016

  Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
• 
  Story Jun 07, 2016 Discovery

  The eye: the fastest muscle in the human body

  How much do you know about eyes? Learn more about the fastest muscle in the human body.

• Press release Jun 06, 2016

  Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

  Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy  Latest data show an estimated 44% of…
• Press release Jun 06, 2016

  Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

  The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months   Efficacy analyses also presented for INC280 (…
• 
  Story Jun 06, 2016 Access to Healthcare

  Fighting pneumonia, the biggest killer of young children

  Pneumonia causes around 2 million child deaths per year globally and the burden is especially heavy in a country like Bangladesh, where a third of the population is aged 14 or below.

• 
  Story Jun 06, 2016 Patient Perspectives

  Lung Cancer: To test or not to test

  For patients with lung cancer, biomarker testing may be an option.